This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Evaluation of 130 Cases and Review of the Literature Regarding Concordance With Biochemical Assay and Clinical Relevance

D. Craig Allred, MD; Mario A. Bustamante, MD; Craig O. Daniel, MD; Harold V. Gaskill, MD; Anatolio B. Cruz, Jr, MD

Arch Surg. 1990;125(1):107-113.

Abstract
• An estrogen receptor–immunocytochemical assay (ER-ICA) was performed on frozen sections of 130 samples of human breast carcinoma. A standard dextran-coated charcoal assay (DCCA) was performed on the same samples. Concordance of results between the tests was 91%. The sensitivity and specificity of the ER-ICA, compared with the DCCA, were 92% and 89%, respectively. We describe the ER-ICA technique and review the literature regarding the use of the ER-ICA in evaluating breast cancer with respect to the agreement of results with the DCCA, the nature of discordant results, the ability to predict the clinical response to hormone therapy, and the ability to predict disease-free survival. The combined experience of many studies has shown that the ER-ICA is a highly specific and sensitive method for measuring the level of ERs in breast tumors with a high level of agreement with the DCCA. Early experience has suggested that the ER-ICA can predict the response to hormone therapy and disease-free survival, as well as or better than the DCCA. The evaluation of receptor heterogeneity, made possible by the ER-ICA, may enhance our ability to discriminate ER-positive tumors with a relatively high risk of recurrence.

(Arch Surg. 1990;125:107-113)

Author Affiliations
From the Departments of Pathology (Drs Allred and Bustamante) and Surgery (Drs Daniel, Gaskill, and Cruz), University of Texas Health Science Center, San Antonio.

Footnotes
Accepted for publication June 22, 1989.

Reprint requests to Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr, San Antonio, TX 78284 (Dr Allred).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol
Peterson et al.
JNM 2008;49:367-374.
ABSTRACT | FULL TEXT  

The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
Rugo
Ann Oncol 2008;19:16-27.
ABSTRACT | FULL TEXT  

High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients
Stendahl et al.
Clin. Cancer Res. 2006;12:4614-4618.
ABSTRACT | FULL TEXT  

Reliance on Hormone Receptor Assays of Surgical Specimens May Compromise Outcome in Patients With Breast Cancer
Mann et al.
JCO 2005;23:5148-5154.
ABSTRACT | FULL TEXT  

Use of Electric Bedding Devices and Risk of Breast Cancer in African-American Women
Zhu et al.
Am J Epidemiol 2003;158:798-806.
ABSTRACT | FULL TEXT  

Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening
Rhodes et al.
J. Clin. Pathol. 2000;53:688-696.
ABSTRACT | FULL TEXT  

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
Harvey et al.
JCO 1999;17:1474-1474.
ABSTRACT | FULL TEXT